NCT05464719View on ClinicalTrials.gov

A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy

PHASE2RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

September 23, 2022

Primary Completion Date

January 30, 2026

Study Completion Date

January 30, 2026

Conditions

Large B-cell LymphomaLymphoma

Interventions

DRUG

Loncastuximab Tesirine

Given by IV

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

All Listed Sponsors

lead

M.D. Anderson Cancer Center

OTHER